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Blunted cGMP response to agonists and enhanced glomerular cyclic
3 ,5 '-nueleotide phosphodiesterase activities in experimental congestive
heart failure. The natriuretic peptide (NP) and nitric oxide (NO) systems
are activated in congestive heart failure (UHF), resulting in increased
synthesis of cGMP, which serves as a second messenger for both humoral
systems. These Iwo regulatory systems play functional roles in the preser-
vation of glomerular filtration rate (GFR) and sodium excretion in both
acute and chronic UHF. A progressive decline in glomerular responsive-
ness to atrial natriuretic peptide (ANP) characterizes the terminal stage of
chronic UHF despite elevation of plasma ANP. Phosphodiesterase
isozymes (PDEs) are integral factors in determining cellular content and
accumulation of eGMP, and up-regulation of PDE activity could partici-
pate in the glomerular resistance to ANP in severe UHF. To date,
characterization of possible alteration of glomerular PDE isozyme activ-
ities in CHF is unknown, as is the in vitro glumerular response to the nitric
oxide-soluble guanylyl eyelase pathway. We, therefore, first determined
cOMP generation in response to particulate and soluble guanylyl cyeiase
activation by ANP and sodium nitroprusside (SNP) in isolated glomeruli
from normal (N = b) and UHF dogs (N = 5) in which UHF was induced
by rapid ventricular pacing for IS to 28 days. Secondly, we explored the
presence of major PDE isozymes in glomeruli isolated from the control
and CHF dogs. When ANP or SNP (10 '"to t0 vi) were incubated with
the suspension of isolated glomeruli, cOME accumulation was lower by
—72 to —96% with ANP and —42 to —77% with SNP in all glomerular
medias obtained from UHF compared to controls. PDE hydrulyzing
activity of both cAMP and eGMP were higher in the glumerular homog-
enates obtained from the kidneys of the UHF group (N = 5) compared to
those of the control group (N = 5). We conclude that in severe chronic
experimental UHF, glomerular eGMP accumulation decreases in response
to both ANP and SNP, and UHF is characterized by enhanced cAMP- and
eGMP-PDE activities that may participate in glomerular maladaptation to
this cardiovascular syndrome.
Activation of the natriuretie pepfide system (NPS), which
includes atrial (ANP), brain (BNP) natriuretic peptides of myo-
eardial cell origin [1, 21, and C-type (CNP) natriuretic peptide of
endothelial [3] and renal cell origin [4], is a hallmark of chronic
congestive heart failure (CHF) [5]. In addition to the NPS, the nitric
oxide (NO) system is also activated in chronic UHF [6, 7]. Both
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humoral systems function through particulate and soluble guanylyl
eyelases respectively resulting in an increase in eGMP generation.
While the NPS and NO play important roles in the preservation of
renal hemodynaniics and sodium excretion in both acute and chronic
heart failure [5—121, the terminal stage of UHF is characterized by
decreases in glomerular filtration rate (GFR) and sodium excretion
in addition to reduced glomerular and natriuretie responsiveness
to exogenous ANP [13] and BNP [14]. While the mechanisms
which mediate this glomerular hyporesponsiveness to NPS stim-
ulation in UHF remain poorly defined, they may be multifactorial
and include decreased number or reduced affinity of biological
receptors or post-receptor events that may lead to reduced stimula-
tion of guanylyl eyelases and/or an increased cGMP degradation.
Phosphodiesterase enzymes (PDEs) mediate hydrolysis of both
cAMP and eGMP [I5[. To date, seven major types of PDEs have
been isolated and characterized. The first five include POE-I
(ealeium-ealmodulin dependent), POE-Il (cOMP-stimulated),
and POE-ill (cGMP inhibited), hydrolyse both cAMP and eGMP
while POE-TV (cAMP-specific) hydrolyses only cAMP and
POE-V hydrolyses only eGMP. While five types of POEs are
present in rat glomeruli [16], their activities in UHF remain
undefined.
Therefore, the current investigation was designed to address
two objectives. First, we determined the ability of ANP and SNP
to enhance eGMP accumulation in isolated glomeruli from nor-
mal and UHF canine kidneys. Second, we determined the activi-
ties of five types of FOEs in glonieruli from normal and UHF
dogs. We hypothesized that in overt UHF, total POE activity in
isolated glomeruli would be increased and glornerular eOMP
accumulation to ANP and SNP would be reduced. To test this
hypothesis, glomeruli were isolated from canine kidneys in the
presence and absence of overt UHF produced by three weeks of
rapid ventricular pacing. This model is characterized by avid
sodium retention in association with altered renal hemodynamie
function, marked ventricular dysfunction, systemic vasoconstrie-
tion, and neurohumoral activation thus mimicking severe human
UHF [10, 11, 17—20].
Methods
Animal model
Studies were conducted in two groups of male mongrel dogs
(weight, 18 to 22 kg) in accordance to the Animal Welfare Act.
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The first group served as normal controls (Control group, N = 6)
and the second group (CHF group, N = 5) served as the CHF
group in which severe CHF was produced by chronic rapid
ventricular pacing at a pacing rate of 245 beats/mm for 21 days.
Hemodynamics, renal function and neurohumoral function were
assessed twice in the CHF group before pacing and after the
appearance of signs and symptoms of CHF.
In a sterile surgical suite, adult male mongrel dogs were
anesthetized utilizing pentobarbital sodium anesthesia at a dose
of 30 mg/kg i.v. for induction and repeated dosing as needed for
maintenance of anesthesia. Supplemental oxygenation at 5 liter!
mm was provided via endotracheal tube utilizing a Harvard
respirator, (Harvard Apparatus, Millis, MA, USA). A program-
mable cardiac pacemaker (Medtronic, Minneapolis, MN, USA)
was implanted via a left thoracotomy with a 1 to 2 cm pericar-
diotomy. Following the pericardiotomy, the heart was exposed
and a screw-in epicardial pacemaker lead was implanted into the
right ventricle. The pacemaker lead was connected to a pulse
generator which was then implanted subcutaneously in the chest
wall. Pacing capture was verified intraoperatively prior to closing
the chest cavity. The pericardium was then sutured close with
great care not to distort the anatomy of the pericardium. The
chest cavity and incisions were then closed in layers.
A chronic femoral artery catheter (Model GPV Vascular-
Access Port, Access Technologies, Skokie, IL, USA) for mean
arterial pressure monitoring and arterial plasma sampling was
placed in each dog during the sterile surgical procedure. The
catheter was implanted into the left femoral artery with the
self-sealing silicone rubber septum port tunneled subcutaneously
to the left upper hind limb. Prophylactic antibiotic treatment with
225 mg clindamycin subcutaneously and 400,000 U procaine
penicillin G plus 500 mg dihydrostreptomycin intramuscularly
(Combiotic; Pfizer, Inc., New York, NY, USA) were administered
preoperatively and on the first two post-operative days.
Following a 14 day post-operative recovery period, rapid right
ventricular pacing was initiated at 245 bpm. Each dog was then
continuously paced at 245 bpm through the 21 day protocol.
Pacemaker capture was verified by surface electrocardiogram two
times each week.
The following acute protocol was undertaken in each of the
individual dogs twice: first at baseline, before the onset of
ventricular pacing, and second, after 21 days of ventricular pacing
at 245 bpm. Briefly, for each of the two studies, on the night prior
to the experiment, each dog was fasted, but allowed free access to
water. On the day of the acute experiment, each dog was
anesthetized with thiopental sodium (15 mg/kg, i.v.) to allow
sterile percutaneous placement of a flow-directed balloon tip
pulmonary artery catheter (model 93131-7F; American Edwards
Laboratories, AHS del Carihe, Anasco, PR) via an external
jugular vein. The femoral artery catheter was connected to a
pressure monitor for on-line measurement of aortic pressure and
for blood sampling. A second balloon-tip catheter was inserted in
the urinary bladder for urine collection.
After recovery from anesthesia, each dog was allowed to stand
freely in a minimally restricting sling. After administration of a
loading dose of inulin and PAH, an infusion of an inulin/PAH
solution was infused at a rate of 1 mI/mm via central access to
achieve a stable plasma inulin concentration of approximately 50
mg/dI, Each dog was allowed to stabilize for a 60-minute equili-
bration period prior to measuring any parameters. The study
period consisted of a 30-minute clearance period with hemody-
namics and blood sampling occurring at the midpoint of the
clearance.
During the clearance, the following hemodynamic data were
collected: mean arterial pressure (MAP), right atrial pressure
(RAP), pulmonary artery capillary pressure (PCWP), and cardiac
output (CO). Cardiac output was measured by thermodilution
(American Edwards Cardiac Output Computer model 9510-A).
For each clearance, cardiac output was measured four times and
then averaged. Systemic vascular resistance (SVR) was calculated
as [(mean arterial pressure-right atrial pressure)/cardiac output].
Pulmonary vascular resistance (PVR) was calculated as [(pulmo-
nary artery pressure-pulmonary capillary wedge pressure)/cardiac
output]. Renal vascular resistance (RVR) was calculated as
[(mean arterial pressure — right atrial pressure)/renal blood flow].
Mean arterial pressure was assessed via direct measurement from
the chronic arterial port. Glomerular filtration rate (GFR) was
measured by inulin clearance. Renal blood flow (RBF) was
calculated from estimated renal plasma flow (PAH clearance) and
hematocrit. Urine was collected on ice during the clearance
period for assessment of urine volume, inulin, PAH, endothelin,
and cGMP.
Glomerular isolation and cGMP generation
Dogs were anesthetized with sodium pentobarbital (30 mg/kg)
and kidneys were harvested. The control group underwent eutha-
nasia by harvesting of the kidneys as did the CHF group utilizing
a similar protocol. The control group did not undergo pacemaker
insertion. We have previously reported that neurohumoral func-
tion is not different between a normal control group (as was
utilized in the current study) and a sham operated group that
underwent thoracotomy and cardiac manipulation [21].
Glomeruli were isolated using a minor modification of the
technique of Chaumet-Riffaud et al [22]. Briefly, after the kidneys
were removed, renal cortex was isolated, sliced, minced then
squeezed through sieve with pore sizes of 250 and 212 ,tm,
respectively. After each sieving, the suspension was centrifuged at
160 g for three minutes and the supernatant was discarded. The
final pellet was resuspended and was buttered through a 60 jsm
sieve; the glomeruli which were retained on the sieve were
resuspended, recentrifuged and the supernatant was discarded,
The pellet was resuspended in ice-cold Kreb's buffer, pH 7.4,
containing 135 mivi NaCI, 4.7 mivi KC1, 25 m Na bicarbonate, 1.2
mM, KHPO4, 2.5 mrvt CaCl2, 0.026 m Ca Versanate, and 10 mM
glucose, equilibrated with 95% 02 and 5% CO2. Aliquot of the
final ccntrifugation uniformly yielded material containing > 90%
glomeruli and less than 5% tubular contamination when examined
by light microscopy.
For measurement of ANP-stimulated or NO-stimulated cGMP
accumulation, we used a method employed in our previous studies
on rat kidney glomeruli with a few minor modifications [22, 24]. In
short, aliquots of fresh glomeruli were suspended in Kreb's buffer
and preincubated for 10 minutes at 37°C and incubation was
started by adding synthetic ANP at a concentration of i0° to
10 M or sodium nitroprusside (SNP) at similar range of
concentrations. This was terminated after 10 minutes by adding
ice-cold trichloroacetic acid (TCA), final concentration 6.6%, and
cooling to 4°C then recentrifugcd, and the pellet was dissolved in
I N NaOH and assayed for protein content by the method ol'
Lowry et al [25] using bovine serum albumin as the standard. The
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supernatant fluid, containing cGMP from glomeruli and the
incubation media, was extracted five times with four volumes of
water-saturated ethyl ether to remove the TCA before being
evaporated to dryness under a stream of air and was stored at
—70°C until assayed for cGMP content. For the cGMP assay,
samples were dissolved in 50 m sodium acetate buffer, pH was
adjusted to 6.2 mixed thoroughly, and aliquot acetylated accord-
ing to the manufacturer's instructions (Dupont, Boston, MA,
USA). Averaged results of triplicate determinations were ex-
pressed as fmol cGMP accumulated per 10 minutes of incubation
per mg protein. The supernatant fluid was used for the assay of
cGMP with a method slightly modified from that described by
Imura et a! [26].
Phosphodiesterase (PDE) assay
Homogenization of isolated glomeruli was obtained and ex-
tracted for PDE assays in buffer containing 0.1% Triton X-100 as
mentioned previously [27, 281. The activity of PDE was measured
by incubating the glomerular homogenate in a reaction mixture
(final volume 100 pJ) of the following composition (final concen-
trations): 10 mivi MgSO4, 2 mivi EGTA, 0.1% bovine serum
albumin, 15 mivi Tris-HCI adjusted to pH 7.4, and either 0.5 LM
[3H]-cAMP, or 0.5 tM [3H]-cGMP as substrate [27, 29]. In
experiments examining the activity of Ca2-caImodulin (CaM)-
dependent PDEs, the reaction mixture also contained 2.01 mM
CaC12, to obtain 10 LLM Ca2, and 10 jig/mI of calmodulin (CaM).
The PDE activity in aliquot samples incubated without Ca2 and
CaM (but containing 2 mM EGTA, vide supra) was subtracted as
"basal activity" [27, 29]. Activities of isozymes PDE III and
PDE-IV were determined as cAMP-PDE inhibitable by 3 jiM
cilostamide or 3 jiM rolipram, respectively [281. At these concen-
trations (3 jiM) both rolipram and cilostamide cause maximal
inhibition of corresponding PDEs in rat glomeruli [16]. The PDE
Il-activity was determined as the difference in cAMP-PDE as-
sayed without or with 5 JiM cGMP [281 and PDE-V activity was
demonstrated as the difference in cGMP-PDE without or with 10
JIM zaprinast. This concentration of zaprinast was slightly higher
than that described by Chini et al [16]. In experiments examining
the effect of PDE inhibitors, stock solutions of all inhibitors of
PDE were made in 100% dimethylsulfoxide (DMSO), and the
incubation media (including controls) contained, after final dilu-
tion, 0.1% DMSO. Hydrolysis of c-3',S'-nuc!eotides was less than
20% of the substrate and was linearly proportional to incubation
time and enzyme protein concentration [27—29]. Protein content
was measured by the Bradford's method [30].
Hormone analysis
Arterial blood was collected at the midpoint of the clearance
for analysis of atrial natriuretic peptide (ANP), 3'S' guanosine
monophosphate (cGMP), endothelin (ET), plasma renin activity
(PRA), electrolytes and hematocrit. Plasma ANP was measured
by a specific radioimmunoassay (RIA) as previously described [8].
Briefly, blood for hormone analysis was collected in an ethylene-
diamine-tetraacetic acid (EDTA) tube and immediately placed on
ice. After centrifugation of 2500 rpm at 4°C, plasma was separated
and stored at —20°C until assay. ANP was extracted by use of C18
Bond Elut with recovery of 86%. ANP was measured by a
radioimmunoassay utilizing a specific antibody to human ANP.
Interassay variation was 9%, intra-assay variation was 6%, and
cross reactivity was 100% with canine ANP. Cross reactivity to
BNP or CNP was less than 0.1%.
Plasma endothelin was determined by ET-1,2 [1251] assay
system from Amersham (Amersham, UK). Before the radioim-
munoassay, plasma was acidified with 0.5% trifluoroacetic acid
(TFA). C8 Bond Elut cartridges were washed with 4 ml of
methanol and 4 ml of water to extract the plasma. After the
plasma was applied, cartridges were washed with 2 ml of normal
saline and 6 ml of water. ET was eluded from the cartridges with
2 ml of 90% methanol in 1% TFA, then dried and reconstituted
for the radioimmunoassay. The recovery of the extraction proce-
dure was 81% as determined by the addition of synthetic ET to
plasma; interassay and intra-assay variations were 9% and 5%,
respectively. The minimal level of detection was 0.5 pg per tube.
The cross reactivity of endothelin-2 and -3 and proendothelin in
this assay were < 5%, < 3%, and < 37%, respectively.
Plasma and urinary cGMP was measured by radioimmunoassay
using previously described methods [31—33]. Plasma renin activity
was measured by radioimmunoassay as previously described [34].
Glomerular filtration rate was determined by the clearance of
inulin. Urinary and plasma inulin concentration was measured by
the anthrone method. Urinary and plasma electrolytes were
determined by flame emission spectrophotometiy (model 357;
Instrumentation Laboratory, Wilmington, MA, USA).
Materials
Synthetic h a-ANP was purchased from Phoenix Laboratories
(Mountview, CA, USA), sodium nitroprusside was from Sigma
Chemical Co. (St. Louis, MO, USA), The cGMP Kit was pur-
chased from Dupont Co. Inc. (Boston, MA, USA). The cAMP
and cGMP were from Sigma Chemical Co.; [3H]-cAMP and
[3H]-cGMP (ammonium salt 30 to 50 Ci/mmol) were from
Amersham Co. (Arlington Heights, IL, USA). Cilostamide was a
gift from Parke-Davis Pharm. (Warner-Lambert Co., Ann Arber,
MI, USA). Rolipram was purchased from Biomol. Zaprinast was
purchased from Sigma Chemical Co. All other reagents and
chemicals were of the highest purified grade and were purchased
from standard suppliers. [3H]-cAMP and [3H1-cGMP were, prior
to use as substrates in PDE assays, purified according to a method
of Kincaid and Manganiello [35].
Statistical analysis
Data were expressed as mean SEM. All data from each
experimental group were compared and analyzed by ANOVA for
repeated measures with Fisher's exact for the least significant post
hoc test applied when appropriate. The comparison between
groups was analyzed by ANOVA and unpaired t-test when
appropriate. Statistical significance was accepted for P < 0.05.
Results
Cardiovascular, renal and hormonal Jltnction
Table 1 reports cardiovascular, renal, hormonal function before
and after the development of overt CHF, Right atrial pressure
(RAP) and pulmonary capillary wedge pressure (PCWP) in-
creased while mean arterial pressure (MAP), cardiac output
(CO), and urinary sodium excretion (UNaV) decreased during
CHF. Glomerular filtration rate (GFR) tended to decrease in
association with a marked decrease in renal blood flow (RBF).
Plasma ANP, cOMP and ET increased during CHF while PRA
increased but not significantly.
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Table 1. Hemodynamics, Renal Function and Sodium Excretion, and
Hormonal Function from CHF Group Before and During
Symptomatic CHF
Baseline CHF
MAP mmHg 122 3 109 2*
RA mmHg 5.6 0.6 15.4 1.7*
PCWP mmHg 9.8 0.4 33 1.9*
CO L/min 5.3 0.3 2.2 0.1*
SVR R.U. 22 2 42 1*
GFR mI/mm 119 15 94 30
RBF mI/mm 456 83 217 41*
UNaV mEq/min 171.0 41.2 25.7 59*
P-ANP pG/mi 38 8 970 118*
PRA nglml/min 0.5 0.2 1.6 0.8
P-ET pG/mi 3.7 1.4 11 1.8*
P-cGMP pM/mi 1.9 0.9 7.2 1.2*
Data in Mean SEM; * denotes p < 0.05 compared to baseline: MAP,
mean arterial pressure; RA, right atrial pressure; PCWP, pulmonary
capillary wedge pressure; CO, cardiac output; SVR, systemic vascular
resistance; GFR, glomerular filtration rate; RBF, renal blood flow; UNaV,
urinary sodium excretion; P-ANP, plasma atrial natriuretic peptide; PRA,
plasma renin activity; P-cGMP, plasma cGMP; P-ET, plasma endothelini
cGMP accumulation in isolated glomeruli
Accumulation of cGMP generated in incubated glomeruli
increased dose-dependently in response to added ANP (Fig. 1A)
reaching plateau at 10 to iO M ANP. Incubation with SNP
also resulted in a dose dependent increment of accumulated
cGMP (Fig. 1B), however, the total amount of accumulated
cGMP was many-fold less than with ANP (P < 0.05). In CHF, less
glomerular cGMP accumulation was observed compared to nor-
mal control at all concentrations of ANP (P < 0.05) or SNP at
iO M of SNP (P = 0.059). Table 2 demonstrates 72 to 96% less
cGMP accumulation in the incubation medias of CHF glomeruli
compared to control after incubation with different concentra-
tions of ANP, and 42 to 77% less cGMP accumulation after
incubation with different concentrations of SNP.
Phosphodiesterase activity in isolated glomeruli
PDE isozyme activities, defined by cAMP, cGMP hydrolysis
and the type specific criterias as mentioned earlier in the Methods
section, are depicted in Figures 2, 3 and 4, Figure 2 A and B report
activities of each type of cAMP- and cGMP-PDE hydrolyzing
activities, respectively, from normal controls without (basal) and
with stimulation or inhibition by type-specific agents. Figure 2A
illustrates that calcium-calmodulin did not enhance cAMP hydro-
lysis hut cGMP increased the cAMP hydrolysis from the basal
activity. The cAMP-hydrolyzing PDE activities were specifically
inhibited by cilostamide and rolipram. Figure 2B reports the
cGMP hydrolyzing PDE activities without (basal), and with
calcium-calmodulin, or with zaprinast in glomeruli from normal
controls. Calcium/calmodulin enhanced cGMP-hydrolyzing PDE
activity significantly and zaprinast tended to attenuate the cGMP-
hydrolyzing PDE activity from the basal activity.
Figure 3 A and B illustrates the higher basal PDE activities in
the CHF group compared to the control group for both hydrolysis
of cAMP and cGMP, respectively. Figure 4 A and B compares
activities of each type of cAMP- and cGMP-hydroiyzing PDEs
between the control and CHF groups, and without (basal) and
with stimulation or inhibition with type-specific agents. In contrast
to the control group, both parts of Figure 4 illustrate higher PDE
activities in the CHF group by stimulation or inhibition with the
type specific agents.
Figure 4A indicates that cAMP hydrolyzing activity of the
glomeruli from the CHF group was enhanced (29%) by the
calcium-calmodulin, while a slight enhancement of the activity
occurred in the control group (5%). Enhanced cAMP hydrolyzing
PDE activity was observed by 38% in both the CHF and the
control groups by cGMP. Attenuation of cAMP-hydrolysis in
CHF group were observed by cilostamide (—25%) and rolipram
(—32%), and these observations were similar to the control group
(—35% by cilostamide and —38% by rolipram, respectively), hut
higher PDE activities after the inhibition were observed in the
CHF group.
In the CHF group, Figure 4B illustrates calcium-calmodulin
enhanced cGMP-PDE hydrolysis (58%) from the basal activity,
while zaprinast attenuated the cGMP-PDE hydrolysis (31%)
below the basal activity. The PDE activities in the presence of
calcium-calmodulin and zaprinast of the CHF group tended to be
higher than of the control group.
Discussion
The current studies were designed to provide further insight
into the glomerular hyporesponsiveness to atrial natriuretic pep-
tide and sodium nitroprusside in a canine model of overt CHF.
The current studies demonstrate that these two agonists to
particulate and soluble guanylyl cyclases are characterized by a
reduced ability to accumulate cGMP in isolated glomeruli from
dogs with overt CHF. Second, these studies provide new insight
into alterations in glomerular PDEs and demonstrate for the first
time enhanced cAMP and cGMP hydrolysis in CHF. These
studies therefore extend previous investigations and provide a
possible mechanism by which glomerular responses to humoral
factors that are linked to the cyclic nucleotides, cAMP and cGMP,
occur in CHF.
Rapid ventricular pacing induced heart failure has been widely
accepted as a model which results in the hemodynamic, renal, and
neurohumoral adaptations which mimic those of human heart
failure [10, 11, 18—201. Recently, we have reported in preliminary
studies that in acute heart failure (AHF), despite decreased CO
and MAP, GFR and urinaly sodium excretion are well maintained
in the presence of activation of the NPS with enhanced cGMP
generation [12]. Such a compensatory renal response to AHF
occurs in the absence of activation of the renin-angiotensin-
aldosterone system similar to the early phase of chronic heart
failure observed early in human and experimental CHF [10, 11,
17—20]. In this preliminary report, we also observed that the NO
system functions to maintain renal blood flow in AHF [12].
In contrast to AUF, overt CHF is characterized by a giomerular
and tubular resistance to exogenous ANP [13]. Such a renal
resistance is associated with a reduced cGMP response to exoge-
nous ANP [36] with a blunted increase in GFR [37] and an
attenuated cGMP response to ANP in isolated glomeruli [381. In
the present studies, we explored mechanisms of this glomerular
resistance to ANP and to an agonist of the soluble guanylyl cyclase
pathway. Specifically, we utilized isolated glomeruli for studying
cGMP accumulation and PDE activities based upon the knowl-
edge that the NPS and NO system induce marked generation of
cGMP in glomeruli, particularly in epithelial cells (podocytes) and
mesangial cells [39, 40]. Although a reduced cGMP response in
glomeruli from CHF kidneys has been reported with ANP,
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Fig. 1. Accumulation of cGMP in the incubation media of glomerular suspension with incremental concentration from 10— to io M of ANP (atrial
natriuretic peptide, A) and SNP (sodium nitroprusside, B), compared between control group and heart failure group. Data are expressed in means SEM
in fem to mole per mg of glomerular protein; C denotes 0 M Concentration of ANP in (A) and SNP in (B), respectively; * < 0.05 compared to normal
and §P = 0.059 compared to normal; tP < 0.05 compared to 0 M concentration of the stimulating agent used in the same group. Symbols are: (LI)
control; (L) CHF.
Table 2. The rclative differences of mean cGMP accumulation between CHF and control glomeruli in percent of control glomeruli after 10
minutes of incubation with ANP or SNP at concentration of 10 to iO M respectively
Concentration of ANP or SNP (M) i0-'° i0 108 i0 i0 10 iO
cGMP accumulation after incubation with ANP (%) —76 —72 —77 96* 90* 87* 79*
cGMP accumulation after incubation with SNP (%) —67 —61 —52 —67 —42 —49
—77
ANP, atrial natriuretic peptidcs; SNP, sodium nitroprusside
cGMP accumulation = [(cGMP accumulation from CHF glomeruli-cGMP accumulation from control glomeruli)/cGMP accumulation from control
glomeruli] X 100; *Denotes p < 0.05 compared cGMP accumulation between the CHF and the control glomeruli, and § denotes p = 0.059 compared
cGMP accumulation between the CHF and the control glomeruli after stimulation by SNP
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Fig. 2. Glomendarphosphodiesterase (I'DE) normal dogs express per minute per mg of glomerular homogenizing protein in basal condition (Basal), calcium
cal,nodulin stimulated c AMP or cGMP hydrolyzing PDE-I (Ca-CaM), cGMP stimulated cAMP PDE-!f (cGMP, cilostamide inhibited cAMP hydrolyzing
PDE-IIl (Cs), rolipram inhibited I'DE-IV (Rp), and zaprinact inhibited hydrolyzing PDE-V (Zap). Doted line represents the level of basal PDE hydrolyzing
activity. Data are expressed as means SaM; tP < 0.05 compared to basal activity.
controversy continues to persist [38, 41—431. Levin et al reported shunt in rat, Abassi et al found cGMP accumulation from
that cGMP generation after stimulation with ANP in glomeruli glomeruli to be higher in CHF [42] while Garcia, Borihomme and
from cardiomyopathic hamsters with CHF was lower than in Schiffrin reported lower generation of glomerular cOMP in the
normal hamsters [38]. In contrast, Luk et al reported glomerular same model of CHF in the presence of elevation of PRA
cGMP responses to ANP or BNP in hamster cardiomyopathy and compared to normal control rats [43]. In the current study, the
CHF was higher than control [411. In CHF induced by aortocaval finding of a reduced glomerular response to ANP is consistent
cAMP Hydrolysis
(basal POE activity)
cAMP Hydrolysis
(basal PDE activity)
A B
1000
1; 800
600
400
200
0
1000
800
600
400
200
0
Supaporn et a!: Glomerular cGMP and PDEs in CHF 1723
Fig. 3. Basal glomerular phosphodiesterase
(Basal) hydrolyzing activities of cAMP (A) and
cGMP (B) after five minutes of incubation per
mg of glomendar homogenizing protein,
compared between the control group () and the
heart failure group (E1 N = 5 in each group).
Data are expressed as means SEM; P < 0.05
compared between heart failure group and
control.
Fig. 4. Glomendar phosphodiesterase (PDE) hydrolyzing activities of cAMP (A) and cGMP (B) express per minute per mg of glomendar homogenizing
protein in basal condition (Basal), calcium calmodulin stimulated cAMP or cGMP hydrolyzing PDE-1 (Ca-CaM), cGMP stimulated cAMP PDE-JI (cGMP),
cilostamide inhibited cAMP hydrolyzing PDE-II1 (CS), rolipram inhibited PDE-I V (RP), and zaprinast inhibited hydrolyzing PDE-V (Zap), compared between
control group and heart ftuilure group (N = 5 in each group). Data are expressed as means SEM; *p < 0.05 compared between the heart failure group
and controls, tP < 0.05 compared to basal activities of each group. Doted lines ( or ) indicate the levels of baseline cAMP (A)
or cGMP (B) hydrolysis PDE activities obtained from the control and CHF groups, respectively.
with Leviri et a! and Garcia et a!. Moreover, we extended these
observations and also established that the soluble guanylyl cyclase
pathway is also involved as demonstrated by the attenuated
response to SNP in CHF. However, we are aware that species
difference in renal responsiveness between rat and dog might exist
and this needs to be investigated further.
The glomerular cGMP response to ANP was higher than the
response to SNP, in isolated glomeruli from dogs either with or
without CHF. In the present study, glomeruli were incubated with
agonists as described and, at the end of incubation, TCA was
added to inactivate all enzymes and disrupt glomeruli. As in our
previous studies [23, 24, 44], we measured total accumulation of
cGMP which includes intracellular cGMP in glomerular cells and
cGMP effused into medium. The amount of cGMP accumulation
is related to protein from glomeruli. This established method is
well suited to detect differences in capacity of ANP-sensitive and
NO-sensitive systems in glomeruli from CHF dogs and controls.
The amount of cGMP that effused into the media escapes
hydrolytic action of PDEs that are endocellular enzymes. It was
also shown that ANP-guanylyl cyclase catalyzes cGMP formation
close to plasma membrane [451. The ANP-stimulated cGMP likely
escapes to extracellular media more readily than cUMP pool
synthetized by cytoplasmic guanylyl cyclase that is stimulated by
NO. This interpretation is consistent with localization of cOMP
generated in response to ANP or SNP analyzed by immunocyto-
logic methodology [451. Also, our findings are consistent with
investigation on aortic strips [461 that show that ANP increased
cGMP synthesis and extrusion into the incubation media whereas
SNP elevated only intracellular content of cGMP. The observa-
tion that cGMP accumulation in CHF was lowered to the same
% relative degree in ANP-stimulated or SNP-stimulated glomer-
uli is consistent with the notion that increased hydrolysis of
cGMP-PDE in CHF was an underlying cause of the difference.
In the present studies, we assayed both cAMP and cGMP
hydrolyzing PDE activities since both intracellular signaling sys-
tems are essential and may adapt differently in CHF. In glomeruli
from normal dogs, cAMP hydrolysis by PDE was elevated by
cGMP and depressed by cilostamide and rolipram, but remained
unchanged after calcium-calmodulin. This suggests that PDE-II,
-III, and -IV activities exist and respond promptly to their
stimulation in the control of cAMP in canine glomeruli. Addition-
ally, our data that calcium-calmodulin induced elevation of PDE
hydrolysis of cGMP also underscores the preference of cGMP as
the substrate of hydrolysis of PDE-T. In addition, zaprinast, a
specific PDE-V inhibitor depressed cGMP-hydrolysis activity
slightly without a statistical significant difference, suggesting that
the PDE-V present in this tissue may possibly have low sensitivity
to this antagonist.
In CHF, we observed that cAMP hydrolysis by PDE in glomer-
uli was elevated by calcium-calmodulin and by cGMP. Addition-
ally, cilostamide and rolipram depressed cAMP hydrolysis. For
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cGMP as a substrate, calcium-calmodulin increased while zapri-
nast depressed hydrolysis. These findings indicate the presence of
all five types of PDE in canine glomeruli, and that all types play
active roles in prompt hydrolysis of cAMP and cGMP in CHF.
Both basal cAMP and cGMP hydrolytic activities of PDE from
glomeruli of CHF were higher than those obtained from normal
glomeruli, suggesting that the environment of CHF had activated
all or some PDE types, particularly PDE-I and PDE-V. The
current study supports a need to further assess cGMP accumula-
tion in isolation from degradation. This, however, should be done
with specific isozyme PDE antagonists for PDE-I, PDE-IV, and
PDE-V.
Studies by Haneda et al may provide insight into mechanisms
which activate PDEs in CHF [47]. These investigators demon-
strated that angiotensin II and other calcium stimulating peptides
inhibited ANP induced cGMP accumulation in cultured rat
glomerular mesangial cells. By employing a specific calmodulin
inhibitor, phosphodiesterase inhibitor, protein kinase C inhibitor,
calcium inophore, and an activator of protein kinase C, two
mechanisms were advanced. The first one involved the activation
of calcium-dependent, calmodulin-stimulated nucleotide phos-
phodiesterase, and the second involved the inhibition of guanylyl
cyclase resulting from protein kinase C activation. As ET-1 is
known to increase intracellular calcium, calcium-calmodulin de-
pendent-PDE could be activated. Thus, increases in plasma ET-i
as observed in the present studies and in other studies [48—50],
could play a role in PDE activation in overt CHF.
In the current study, the marked reduction in cGMP accumu-
lation in isolated glomeruli to ANP occurred in association with a
modest but significant increase in basal cGMP hydrolyzing PDE.
Such alteration in dynamics of cyclic nucleotide in disease is not
without precedent. For example, Homma et al [51] investigated
the role of PDEs in pathogenesis of murine nephrogenic diapedes
insipidus (ND!) and reported that a doubling of basal PDE
activity in inner medullary collecting duct cells (IMCD) of ND!
(control vs. ND!, 31.1 2.8 vs. 75.9 9.6 fmol cAMP min'
mm tubule I) was associated with greater than a 40 times
decrease in cAMP accumulation in IMCD of NDI in the response
to l0' NI vasopressin (control vs. NDI, 45.8 15.6 vs. 1.2 0.2
fmol cAMP mm tubule). Thus, previous studies and other
studies in IMCD have demonstrated that a modest change in PDE
activity may have marked and profound effects upon reducing the
generation of cyclic nucleotides to humoral stimulation [51—54].
The current studies suggest that the marked alteration in cGMP
accumulation with less degree of enhancement of cGMP-PDE
hydrolysis are consistent with this concept.
While the current studies were not designed to provide thera-
peutic insights into glomerular alterations in CL-IF, the current
findings, however, suggest a role and mechanism of action of PDE
inhibition in augmenting glomerular function in response to ANP
in CHF as suggested in vivo by Margulies et a! [55]. In this recent
study, a specific PDE-V inhibitor, zaprinast, iniproved renal
function. The glomerular response to PDE-V inhibitor alone or
with ANP improved GFR and sodium excretion. Further studies
are required to pursue this therapeutic potential.
In summary, in overt CHF, we demonstrate in isolated canine
glomeruli reduced cGMP accumulation in CHF to ANP and SNP.
For the first time, we demonstrate increased glomerular PDE
activities in CHF with alterations in five subclasses of PDE. These
findings provide new insight into alterations in glornerular func-
tion in CHF that may result in a reduced glomerular responsive-
ness to endogenous humoral ligands linked to cyclic nucleotides in
CHF.
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